β-blockers are not all the same: pharmacologic similarities and differences, potential combinations and clinical implications

6Citations
Citations of this article
23Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

β-blockers are a heterogeneous class, with individual agents distinguished by selectivity for β1- vs. β2- and α-adrenoceptors, presence or absence of partial agonist activity at one of more β-receptor subtype, presence or absence of additional vasodilatory properties, and lipophilicity, which determines the ease of entry the drug into the central nervous system. Cardioselectivity (β1-adrenoceptor selectivity) helps to reduce the potential for adverse effects mediated by blockade of β2-adrenoceptors outside the myocardium, such as cold extremities, erectile dysfunction, or exacerbation of asthma or chronic obstructive pulmonary disease. According to recently updated guidelines from the European Society of Hypertension, β-blockers are included within the five major drug classes recommended as the basis of antihypertensive treatment strategies. Adding a β-blocker to another agent with a complementary mechanism may provide a rational antihypertensive combination that minimizes the adverse impact of induced sympathetic overactivity for optimal blood pressure-lowering efficacy and clinical outcomes benefit.

Cite

CITATION STYLE

APA

Taddei, S., Tsabedze, N., & Tan, R. S. (2024). β-blockers are not all the same: pharmacologic similarities and differences, potential combinations and clinical implications. Current Medical Research and Opinion. Taylor and Francis Ltd. https://doi.org/10.1080/03007995.2024.2318058

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free